23:45 , Jul 18, 2019 |  BC Extra  |  Financial News

Kronos parlays diverse pipeline into $105M series A

The speed at which Kronos assembled a broad small molecule platform against hard-to-target hormone receptors, transcription factors and E3 ligases enabled it to raise a $105 million A round led by seed investors Vida Ventures...
09:05 , Jul 16, 2019 |  BioCentury  |  Finance

As it preps Phase III kidney trial on its own, AM-Pharma raises €116M series C

After Pfizer declined to exercise its option to acquire AM-Pharma, the Dutch biotech has turned to European venture investors for a €116 million ($131 million) series C round to fund a Phase III study of...
20:58 , Jun 13, 2019 |  BC Innovations  |  Finance

Sitting it out: Why some investors are staying out of mega-series A rounds

As series A rounds continue to balloon, some VCs are opting to stay away from super-sized rounds, arguing the large boluses of cash up front can erode financial discipline and constrain exit options, hurting returns....
23:49 , Jun 7, 2019 |  BioCentury  |  Politics, Policy & Law

Levitating Levin: new chair’s ambitious plans to elevate BIO

Jeremy Levin has been talking for years about ways to elevate biopharma business practices and public policy to bypass obstacles that hold back biomedical innovation. As BIO’s new chair, he has a chance to try...
23:14 , Apr 11, 2019 |  BC Innovations  |  Targets & Mechanisms

A venture view of biological white space

Scanning the horizon of translational research, VCs on BioCentury’s scientific advisory board see innate neuroinflammation as a white space area flush with under-tapped angles for drug development, and think the rise of single cell-level data...
08:39 , Apr 3, 2019 |  BC Extra  |  Financial News

AgomAb emerges from stealth with €21M series A

Agonist antibody company AgomAb emerged from stealth with a €21 million ($24 million) series A round led by V-Bio Ventures and Advent France Biotechnology to develop antibodies mimicking growth factors for tissue regeneration. AgomAb Therapeutics...
15:47 , Mar 28, 2019 |  BioCentury  |  Product Development

Contracting practices limiting U.S. biosimilars uptake

The U.S. biosimilars market lags Europe’s and won’t catch up until physicians understand and become comfortable with the concept of similarity, Sheila Frame, who heads up Sandoz’s North American biosimilars business, told BioCentury. To create...
12:21 , Mar 26, 2019 |  BC Innovations  |  Distillery Therapeutics

Pore-forming peptide for multiple bacterial infections

DISEASE CATEGORY: Infectious disease INDICATION: Escherichia; Pseudomonas; Staphylococcus In silico and cell culture studies identified a pore-forming peptide that could help treat E. coli , Pseudomonas and Staphylococcus infections. Molecular dynamics simulations of polyleucine-based peptide...
22:35 , Mar 14, 2019 |  BC Extra  |  Company News

Management tracks: Sandoz CEO steps down, C4T hires NIBR's Crystal as CMO

Richard Francis said he will step down as CEO of Sandoz , the biosimilars and generics unit of Novartis AG (NYSE:NVS; SIX:NOVN), effective March 31. Francis said Thursday, "As we announced earlier this year, Sandoz...
14:34 , Mar 14, 2019 |  BioCentury  |  Politics, Policy & Law

Love it or hate it, the myopic IPI won’t lower Medicare drug prices

The Trump administration has proposed that the U.S. pay similar prices to what companies charge in Europe, starting with drugs covered under Medicare Part B. The administration figures that pegging U.S. prices to an International...